Multidisciplinary Head and Neck Cancer Symposium in Phoenix

NewsGuard 100/100 Score

The Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM, will host two news briefings on top head and neck cancer research from its meeting February 25-27, 2010, in Phoenix.

What:Two audio news briefing from the Multidisciplinary Head and Neck Cancer Symposium. (Audio recordings and slides available after the news briefings on ASTRO's Web site (www.astro.org/pressroom/presskit).

When: Thursday, February 25, at 7:00 a.m. Mountain time (9:00 a.m. Eastern time)
Study findings previewed:
•Larynx preservation treatments result in low instance of severe voice disability, nutritional dysfunction.
•Proton therapy shows encouraging long-term outcomes for patients with locally-advanced sinonasal cancers.

How: Register for the webcast at https://astro.webex.com/astro/j.php?ED=119027472&RG=1&UID=0&RT=MiMxMQ%3D%3D. You will receive a confirmation e-mail with instructions for joining the meeting.

You may have the webcast call you directly or you may dial in to one of the numbers below.
*Call-in toll-free number (U.S./Canada): 1-866-699-3239
*Call-in toll number (U.S./Canada): 408-792-6300
*Access code: 686 481 081

When:Friday, February 26, at 7:00 a.m. Mountain time (9:00 a.m. Eastern time)
Study findings previewed:
•Pretreatment SUV associated with head and neck cancer treatment outcomes may help decided treatment plans.
•Concurrent accelerated radiation does not improve outcomes, lowers toxicity over standard radiation in head and neck cancer patients.

How: Register for the webcast at https://astro.webex.com/astro/j.php?ED=119027572&RG=1&UID=0&RT=MiMxMQ%3D%3D. You will receive a confirmation e-mail with instructions for joining the meeting.

You may have the webcast call you directly or you may call in to one of the numbers below.
*Call-in toll-free number (U.S./Canada): 1-866-699-3239
*Call-in toll number (U.S./Canada): 408-792-6300
*Access code: 681 490 414

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Insilico Medicine's AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy